Skip to main content
Top
Published in: Infection 5/2022

Open Access 24-02-2022 | Vaccination | Original Paper

Strategies to successfully prevent COVID-19 outbreak in vulnerable uro-oncology patient population

Authors: Alexander Tamalunas, Melanie Schott, Troya Ivanova, Severin Rodler, Volker Heinemann, Christian G. Stief, Jozefina Casuscelli

Published in: Infection | Issue 5/2022

Login to get access

Abstract

Purpose

As COVID-19 pandemic persists with variants, and despite effective vaccination campaigns, breakthrough infections surge. We implemented strategies to protect vulnerable patients of the uro-oncologic outpatient clinic. We adopted proactive non-symptomatic risk reduction measures, which include non-symptomatic testing requirements for both patients and health care professionals (HCP), intensified patient tracing and contact reduction by implementation of digital health options. Here, we present our best practice example to safely guide oncology professionals and patients with metastasized genitourinary cancers through the current and future pandemics.

Methods

Solely for this purpose, we created a registry of collected data (current telephone numbers, e-mail addresses, vaccination status). We collected a nasopharyngeal swab from every patient upon presentation for treatment. We implemented bi-weekly RNA-PCR assay tests for HCP with patient contact, and limited personal contact at our facility through digital patient consultations.

Results

We started implementing our COVID prevention model at the beginning of the second wave in September 2020 and included 128 patients with urologic malignancies requiring systemic treatment. After COVID vaccination became available in December 2020, all of our HCP were fully vaccinated within 6 weeks and 97% of our patients (125/128) within 9 months. We performed 1410 nasopharyngeal swabs during in-house visits, thereby detecting two COVID-19 infections among our patients, who both survived and successfully continued treatment. To further reduce personal contact, half of our consultations were fully operated digitally, with 76% (97/128) of our patients participating in our digital health offers.

Conclusion

The willingness of patients and HCPs to participate in the study allowed us to implement strict standards to prepare for the ongoing and future pandemics in outpatient cancer units. Next to general preventive measures such as frequent hand disinfection, wearing facial masks, and keeping distance, an important measure to protect vulnerable uro-oncology patients is the capability to perform virus genome sequencing to trace transmission chains.
Literature
1.
go back to reference Petrosillo N, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:729–34.CrossRef Petrosillo N, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:729–34.CrossRef
2.
go back to reference Rasschaert M, et al. Meeting the challenges in cancer care management during the SARS-Cov-2 pandemic: a retrospective analysis. Cancer Control. 2021;28:10732748211045276.CrossRef Rasschaert M, et al. Meeting the challenges in cancer care management during the SARS-Cov-2 pandemic: a retrospective analysis. Cancer Control. 2021;28:10732748211045276.CrossRef
3.
go back to reference Liang W, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.CrossRef Liang W, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.CrossRef
4.
go back to reference Serraino D, et al. Prevalence, determinants, and outcomes of SARS-COV-2 infection among cancer patients. A population-based study in northern Italy. Cancer Med. 2021;10:7781–92.CrossRef Serraino D, et al. Prevalence, determinants, and outcomes of SARS-COV-2 infection among cancer patients. A population-based study in northern Italy. Cancer Med. 2021;10:7781–92.CrossRef
5.
go back to reference Xia Y, et al. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e180.CrossRef Xia Y, et al. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e180.CrossRef
6.
go back to reference Lee LYW, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–16.CrossRef Lee LYW, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–16.CrossRef
7.
go back to reference Tang LV, Hu Y. Poor clinical outcomes for patients with cancer during the COVID-19 pandemic. Lancet Oncol. 2020;21(7):862–4.CrossRef Tang LV, Hu Y. Poor clinical outcomes for patients with cancer during the COVID-19 pandemic. Lancet Oncol. 2020;21(7):862–4.CrossRef
8.
go back to reference Rodler S, et al. Lessons from the coronavirus disease 2019 pandemic: will virtual patient management reshape uro-oncology in Germany? Eur J Cancer. 2020;132:136–40.CrossRef Rodler S, et al. Lessons from the coronavirus disease 2019 pandemic: will virtual patient management reshape uro-oncology in Germany? Eur J Cancer. 2020;132:136–40.CrossRef
9.
go back to reference Bergwerk M, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474–84.CrossRef Bergwerk M, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474–84.CrossRef
12.
go back to reference Rodler S, et al. Telehealth in uro-oncology beyond the pandemic: toll or lifesaver? Eur Urol Focus. 2020;6:1097–103.CrossRef Rodler S, et al. Telehealth in uro-oncology beyond the pandemic: toll or lifesaver? Eur Urol Focus. 2020;6:1097–103.CrossRef
13.
go back to reference Grill E, et al. Sociodemographic characteristics determine download and use of a Corona contact tracing app in Germany-Results of the COSMO surveys. PLoS ONE. 2021;16:e0256660.CrossRef Grill E, et al. Sociodemographic characteristics determine download and use of a Corona contact tracing app in Germany-Results of the COSMO surveys. PLoS ONE. 2021;16:e0256660.CrossRef
14.
go back to reference Koch-Institut, S.I.b.R. Stellungnahme der Ständigen Impfkommission (STIKO) beim RKI: Bestätigung der aktuellen STIKO-Empfehlungen zur Pneumokokken-Impfung während der Pandemie und Handlungshinweise bei eingeschränkter Lieferbarkeit (Stand: 4.11.2020). 2020(47), p. 27–30. Koch-Institut, S.I.b.R. Stellungnahme der Ständigen Impfkommission (STIKO) beim RKI: Bestätigung der aktuellen STIKO-Empfehlungen zur Pneumokokken-Impfung während der Pandemie und Handlungshinweise bei eingeschränkter Lieferbarkeit (Stand: 4.11.2020). 2020(47), p. 27–30.
15.
go back to reference Root-Bernstein R. Pneumococcal and influenza vaccination rates and pneumococcal invasive disease rates set geographical and ethnic population susceptibility to serious COVID-19 cases and deaths. Vaccines (Basel). 2021;9:474.CrossRef Root-Bernstein R. Pneumococcal and influenza vaccination rates and pneumococcal invasive disease rates set geographical and ethnic population susceptibility to serious COVID-19 cases and deaths. Vaccines (Basel). 2021;9:474.CrossRef
16.
go back to reference Klompas M, et al. Universal masking in hospitals in the covid-19 era. N Engl J Med. 2020;382:e63.CrossRef Klompas M, et al. Universal masking in hospitals in the covid-19 era. N Engl J Med. 2020;382:e63.CrossRef
Metadata
Title
Strategies to successfully prevent COVID-19 outbreak in vulnerable uro-oncology patient population
Authors
Alexander Tamalunas
Melanie Schott
Troya Ivanova
Severin Rodler
Volker Heinemann
Christian G. Stief
Jozefina Casuscelli
Publication date
24-02-2022
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2022
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-022-01775-1

Other articles of this Issue 5/2022

Infection 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine